SEQ ID NO:1

1 DAEFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA

FIG. 1

HVR-H1 (SEQ ID NO:2): GFTFSSYGMS
HVR-H2 (SEQ ID NO:3): SINSNGGSTYYPDSVK
HVR-H3 (SEQ ID NO:4): GDY

HVR-L1 (SEQ ID NO:6): RSSQSLVYSNGDTYLH
HVR-L2 (SEQ ID NO:7): KVSNRFS
HVR-L3 (SEQ ID NO:8): SQSTHVPWT

FIG. 2

HC Sequence (SEQ ID NO:5)

```
  1 EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYGMSWVRQA PGKGLELVAS
 51 INSNGGSTYY PDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCASGD
101 YWGQGTTVTV SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT
151 VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT KTYTCNVDHK
201 PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK DTLMISRTPE
251 VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV
301 LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM
351 TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS
401 RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLG
```

LC Sequence (SEQ ID NO:9)

```
  1 DIVMTQSPLS LPVTPGEPAS ISCRSSQSLV YSNGDTYLHW YLQKPGQSPQ
 51 LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHVP
101 WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK
151 VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE
201 VTHQGLSSPV TKSFNRGEC
```

FIG. 3

	IV (N=249)	
	Placebo (N=84)	Crenezumab (N=165)
Status of AD-Conmed Use		
n	84	165
None	11 (13.1%)	19 (11.5%)
AchEIs Only	50 (59.5%)	96 (58.2%)
Memantine Only	2 (2.4%)	8 (4.8%)
AchEIs and Memantine	21 (25.0%)	42 (25.5%)
ADAS-Cog12: Mild-to-Moderate		
n	84	163
Mean (SD)	27.08 (7.52)	28.87 (9.17%)
Median	26.50	28.33
Min - Max	12.7 - 52.0	7.3 - 55.0

FIG. 4A

	IV (N=249)	
	Placebo (N=84)	Crenezumab (N=165)
Actual Apoe4 Result		
n	84	165
E2/E3	2 (2.4%)	6 (3.6%)
E2/E4	4 (4.8%)	6 (3.6%)
E3/E3	22 (26.2%)	42 (25.5%)
E3/E4	39 (46.4%)	76 (46.1%)
E4/E4	17 (20.2%)	35 (21.2%)
APOE4 Carriers		
n	84	165
NEGATIVE	24 (28.6%)	48 (29.1%)
POSITIVE	60 (71.4%)	117 (70.9%)
MMSE Distribution		
n	84	165
MILD (20-26)	61 (72.6%)	121 (73.3%)
MODERATE (18-19)	23 (27.4%)	44 (26.7%)
MMSE Score at Screening		
n	84	165
Mean (50)	21.60 (2.51%)	21.85 (2.72%)
Median	22.00	22.00
Min - Max	18.0 - 26.0	16.0 - 26.0

FIG. 4B




FIG. 5

IV Cohort ADAS-Cog12: Summary of Week 73 MMRM Results on Observed Case Data

Population	N at Week 73		Placebo LS Mean (SE) Change Score	Crenezumab LS Mean (SE) Change Score	Difference			% Reduction
	Placebo	Crenezumab			LS Mean (SE)	80% CI	P-value	
M2M	64	122	10.85 (1.10)	9.07 (0.81)	1.78 (1.35)	0.04, 3.51	0.19	16%
ApoE4 Negative	21	32	9.34 (2.04)	9.83 (1.59)	-0.50 (2.59)	-3.85, 2.86	0.849*	-5%
ApoE4 Positive	43	90	11.19 (1.29)	8.46 (0.91)	2.73 (1.58)	0.70, 4.77	0.086*	24%
Mild	47	93	10.09 (1.22)	7.85 (0.90)	2.24 (1.47)	0.36, 4.13	0.128*	22%
Mild and ApoE4 Positive	31	68	9.89 (1.37)	6.68 (0.97)	3.21 (1.64)	1.08, 5.33	0.054*	32%
Moderate	17	29	13.83 (2.38)	13.68 (1.89)	0.16 (2.99)	-3.74, 4.05	0.959*	1%

* p values not adjusted for multiplicity

FIG. 6A

IV Cohort ADAS-Cog12: Summary of Week 73 MMRM Results on Observed Case Data									
MMSE Range (% of MITT)	N at Week 73		Placebo LS Mean (SE) Change Score	Crenezumab LS Mean (SE) Change Score	Difference			% Reduction	ES (SD)
	Placebo	Crenezumab			LS Mean (SE)	80% CI	P-value		
18-26 (100%)	64	122	10.56 (1.09)	8.79 (0.79)	1.78 (1.35)	0.04, 3.51	0.190	16.8%	0.20 (9.08)
19-26 (87%)	56	105	10.18 (1.15)	8.07 (0.84)	2.12 (1.42)	0.29, 3.95	0.139	20.80%	0.24 (8.89)
20-26 (74%)	47	93	9.43 (1.20)	7.18 (0.85)	2.24 (1.47)	0.36, 4.13	0.128	23.8%	0.27 (8.44)
21-26 (64%)	39	83	9.22 (1.30)	6.96 (0.90)	2.26 (1.58)	0.22, 4.30	0.157	24.5%	0.27 (8.40)
22-26 (54%)	33	70	9.70 (1.33)	6.26 (0.91)	3.44 (1.61)	1.36, 5.52	0.036	35.4%	0.44 (7.80)
23-26 (43%)	24	60	7.92 (1.44)	5.51 (0.91)	2.40 (1.70)	0.20, 4.60	0.163	30.30%	0.33 (7.18)
24-26 (32%)	16	45	7.41 (1.77)	4.58 (1.06)	2.83 (2.07)	0.15, 5.51	0.176	38.20%	0.39 (7.25)
25-26 (21%)	11	30	6.88 (2.13)	3.51 (1.31)	3.37 (2.50)	0.11, 6.63	0.185	49.00%	0.47 (7.21)

FIG. 6B



Pl: N = 54 N = 51 N = 47
Cr: N = 111 N = 101 N = 93
Crenezumab
Placebo
Week 73
Diff (SE) % Red P-value
IV 2.24 (1.47) 23.8% 0.128
Placebo
Crenezumab
ADAS-Cog12 Change Score
Decline
Improvement
-4
-2
0
2
4
6
8
10
12
14
16
1
25
49
73
Week
Mild AD; MMSE 20-26
Pl = Placebo, Cr = Crenezumab, IV = Intravenous

FIG. 7



Pl: N = 76 N = 71 N = 64
Cr: N = 148 N = 130 N = 122
Crenezumab
Placebo
Week 73
Diff (SE) % Red P-value
IV 1.78 (1.35) 16.8% 0.190
Placebo
Crenezumab
-4
-2
0
2
4
6
8
10
12
14
16
1
25
49
73
Week
Decline
Improvement
ADAS-Cog12 Change Score
Mild to Moderate AD; MMSE 18-26
Pl = Placebo, Cr = Crenezumab, IV = Intravenous

FIG. 8




FIG. 9

ApoE4 Positive Patients:
Pl = Placebo, Cr = Crenezumab, IV = Intravenous



PI IV: N = 36 N = 34 N = 31
Cr IV: N = 80 N = 73 N = 68
Crenezumab
Placebo
Week 73
Diff (SE) % Red P-value
IV 3.21 (1.64) 32.4% 0.054
IV Placebo
IV Crenezumab
ADAS-Cog12 Change Score
Improvement
Decline
-4
-2
0
2
4
6
8
10
12
14
16
1
25
49
73
Week
Mild AD and ApoE4 Positive Patients:
PI = Placebo, Cr = Crenezumab, IV = Intravenous

FIG. 10



ADAS-Cog12 Change Score
improvement
Decline
-4
-2
0
2
4
6
8
10
12
14
16
1
25
49
73
Week
Placebo
Crenezumab
Pl:
Cr:
N = 39
N = 82
N = 36
N = 75
N = 33
N = 70
Week 73
Diff (SE)
% Red
P-value
IV 3.44 (1.61)
35.4%
0.036
Placebo
Crenezumab
Mild AD; MMSE 22-26
Pl = Placebo, Cr = Crenezumab, IV = Intravenous

FIG. 11

IV Cohort CDR-SOB: Week 73 MMRM Results on Observed Case Data									
MMSE Range (% of MITT)	N at Week 73		Placebo LS Mean (SE) Change Score	Crenezumab LS Mean (SE) Change Score	Difference			% Reduction	ES (SD)
	Placebo	Crenezumab			LS Mean (SE)	80% CI	P-value		
18-26 (100%)	67	126	2.57 (0.35)	2.48 (0.25)	0.09 (0.43)	-0.46, 0.64	0.837	3.4%	0.03 (2.94)
19-26 (86%)	58	108	2.65 (0.38)	2.43 (0.28)	0.22 (0.47)	-0.39, 0.83	0.641	8.30%	0.07 (3.02)
20-26 (74%)	48	96	2.18 (0.40)	2.21 (0.28)	-0.02 (0.49)	-0.66, 0.61	0.964	-1.0%	-0.01 (2.91)
21-26 (64%)	40	85	2.26 (0.45)	2.16 (0.31)	0.10 (0.54)	-0.60, 0.81	0.848	4.6%	0.04 (2.98)
22-26 (54%)	34	71	2.24 (0.45)	1.80 (0.31)	0.44 (0.55)	-0.27, 1.14	0.423	19.6%	0.16 (2.75)
23-26 (42%)	24	60	1.88 (0.45)	1.48 (0.28)	0.40 (0.53)	-0.28, 1.08	0.449	21.40%	0.18 (2.25)
24-26 (31%)	16	45	1.87 (0.45)	1.02 (0.27)	0.85 (0.52)	0.16, 1.53	0.114	45.40%	0.46 (1.85)
25-26 (20%)	11	30	1.95 (0.44)	0.71 (0.27)	1.24 (0.52)	0.56, 1.92	0.022	63.60%	0.83 (1.50)

FIG. 12A

			CDR-SOB Total				CDR-SOB Judgment & Problem Solving			CDR-SOB Memory		
MMSE	N (Plc)	N (Cre)	Δ (SE)	Δ %	ES (SD)	P	Δ (SE)	Δ %	P	Δ (SE)	Δ %	P
18-26	67	126	0.09 (0.43)	3.4%	0.03 (2.94)	0.837	0.02 (0.08)	5.7%	0.790	0.08 (0.08)	18.2%	0.311
20-26	48	96	-0.02 (0.49)	-1.0%	0.01 (2.91)	0.964	0.06 (0.09)	16.1%	0.517	0.09 (0.09)	21.7%	0.346
22-26	34	71	0.44 (0.55)	19.6%	0.16 (2.75)	0.423	0.12 (0.10)	29.9%	0.236	0.16 (0.10)	42.7%	0.124

FIG. 12B




FIG. 13

Mild AD; MMSE 25-26
Pl = Placebo, Cr = Crenezumab, IV = Intravenous

	15 mg/kg IV q4w	
	Placebo	**Cren**
Baseline	N=17	N=35
Age	69.8 (7.7)	71.4 (7.1)
Female %	35.3%	68.6%
MMSE	20.5 (2.2)	20.8 (2.3)
MMSE 20-26 (mild)	58.8%	60.0%
APOE4 Carriers	70.6%	68.6%
ADAS-Cog12	34.51 (11.13)	31.21 (9.88)
CDR-SOB	5.9 (1.9)	4.9 (2.0)
ADCS-ADL	64.5 (8.2)	66.8 (7.4)
SUVR (Cerebellar Gray Ref)	1.77 (0.31)	1.74 (0.28)
AChEI and/or Memantine Use	82.4%	91.4%
Completed Treatment	10 (58.8%)	21 (60.0%)
Discontinued Study	7 (41.2%)	14 (40.0%)
Death	0	2 (5.7%)
Adverse Event	3 (17.6%)	1 (2.9%)
Withdrawal by Subject	3 (17.6%)	8 (22.9%)
Other	1 (5.9%)	3 (8.6%)

FIG. 14A



High Dose: 15 mg/kg IV q4w
Amyloid PET
CSF
FDG PET
MRI
MRI
MRI
MRI
Amyloid PET
MRI
MRI
Amyloid PET
CSF
FDG PET
MRI
Baseline
6m
12m
18m

FIG. 14B



0.0500
0.0250
0.0000
-0.0250
-0.0500
Florbetapir SUVR Change from Baseline
Placebo:
Crenezumab:
N = 14
N = 24
N = 10
N = 21
Week 69
PI Cr Diff (SE) P-value
0.025 0.010 0.015 (0.010) 0.131
Baseline
47
69
Week

FIG. 15A



CSF Abeta42 (RPD Elecsys) Change from BL
ANCOVA LSmeans for IV Cohort / M2M
N = 8
N = 17
600
400
200
0
-200
-400
CSF Abeta42 Change from BL (pg/ml)
Week 69
Pl Cr Diff (SE) P-value
-86.65 7.86 -94.51 (37.88) 0.022
Pbo
Week 69
Cren

FIG. 15B



ADAS-Cog12 Change Score
Improvement
Decline
-4
-2
0
2
4
6
8
10
12
14
16
1
25
49
73
Week
Placebo
Crenezumab
Week 73
Diff (SE) % Red P-value
IV -0.78 (2.49) -7.4% 0.755
Placebo
Crenezumab
Pl: N = 26 N = 25 N = 23
Cr: N = 52 N = 46 N = 43

FIG. 16A



ADAS-Cog12 Change Score
Improvement
Decline
-4
-2
0
2
4
6
8
10
12
14
16
1
25
49
73
Week
Pl: N = 35 N = 34 N = 32
Cr: N = 70 N = 61 N = 58
Crenezumab
Placebo
Week 73
Diff (SE) % Red P-value
IV 3.45 (1.54) 35.9% 0.027
Placebo
Crenezumab

FIG. 16B



ADAS-Cog12 Change Score
improvement
Decline
-4
-2
0
2
4
6
8
10
12
14
16
1
25
49
73
Week
Pl: N = 21 N = 20 N = 18
Cr: N = 36 N = 32 N = 30
Crenezumab
Placebo
Week 73
Diff (SE) % Red P-value
IV 1.07 (2.49) 9.1% 0.670
Placebo
Crenezumab

FIG. 17A



ADAS-Cog12 Change Score
improvement
Decline
Week
Crenezumab
Placebo
Pl: N = 22 N = 45 N = 20
Cr: N = 51 N = 44
Week 73
Diff (SE) % Red P-value
IV 2.79 (1.83) 33.3% 0.132
Placebo
Crenezumab

FIG. 17B



ADAS-Cog12 Change Score
Improvement
Decline
-4
-2
0
2
4
6
8
10
12
14
16
Week
1
25
49
73
Placebo
Crenezumab
Pl: N = 19 N = 18 N = 16
Cr: N = 32 N = 28 N = 25
Week 73
Diff (SE) % Red P-value
IV 0.31 (3.25) 3.0% 0.924
Placebo
Crenezumab

FIG. 18A



ADAS-Cog12 Change Score
improvement
Decline
-4
-2
0
2
4
6
8
10
12
14
16
1
25
49
73
Week
Pl: N = 29 N = 28 N = 27
Cr: N = 60 N = 55 N = 52
Crenezumab
Placebo
Week 73
Diff (SE) % Red P-value
IV 3.25 (1.61) 38.9% 0.046
Placebo
Crenezumab

FIG. 18B